Biocon Ltd
BIOCONBiocon Ltd
BIOCON
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 58.13 | 1.29 | 0.62% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 44.48 | 5.11 | 0.70% |
Forecast & Ratings
Detailed Forecastfrom 18 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Biocon Limited is a biopharmaceutical company engaged in the research & development and manufacture of pharmaceuticals, medicinal chemical and botanical products.
Investor Presentation
View olderPeers
Compare with peersHester Biosciences Ltd
Panacea Biotec Ltd
Zenotech Laboratories Ltd
Transgene Biotek Ltd
Vivo Bio Tech Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 3,277.70 | 3,716.70 | 4,064.50 | 4,350.90 | 5,854.30 | 6,529.40 | 7,410.20 | 8,396.70 | 11,550.10 | 14,084.80 | ||||||||||
Raw Materials | 1,308.00 | 1,330.90 | 1,515.60 | 1,677.80 | 2,106.30 | 2,190.30 | 2,533.80 | 2,975.00 | 3,817.20 | 10,953.80 | ||||||||||
| Power & Fuel Cost | 176.70 | 184.70 | 156.40 | 189.00 | 239.80 | 246.10 | 270.30 | 316.40 | 414.80 | |||||||||||
| Employee Cost | 567.20 | 610.10 | 747.00 | 931.10 | 1,165.30 | 1,458.80 | 1,741.00 | 1,880.10 | 2,181.00 | |||||||||||
| Selling & Administrative Expenses | 470.10 | 524.50 | 540.10 | 519.30 | 846.70 | 952.70 | 1,041.70 | 1,158.10 | 1,338.60 | |||||||||||
| Operating & Other expenses | -98.30 | 37.20 | -47.50 | -22.90 | -237.40 | -121.60 | -17.10 | 202.20 | 1,369.30 | |||||||||||
EBITDA | 854.00 | 1,029.30 | 1,152.90 | 1,056.60 | 1,733.60 | 1,803.10 | 1,840.50 | 1,864.90 | 2,429.20 | 3,131.00 | ||||||||||
| Depreciation/Amortization | 221.00 | 248.70 | 277.20 | 385.10 | 447.80 | 552.20 | 715.10 | 814.20 | 1,113.10 | 1,412.10 | ||||||||||
| PBIT | 633.00 | 780.60 | 875.70 | 671.50 | 1,285.80 | 1,250.90 | 1,125.40 | 1,050.70 | 1,316.10 | 1,718.90 | ||||||||||
| Interest & Other Items | 8.90 | 29.30 | 26.00 | 61.50 | 70.90 | 64.90 | 57.70 | 67.60 | 419.00 | 849.80 | ||||||||||
| PBT | 624.10 | 751.30 | 849.70 | 610.00 | 1,214.90 | 1,186.00 | 1,067.70 | 983.10 | 897.10 | 869.10 | ||||||||||
| Taxes & Other Items | 126.70 | 200.90 | 237.60 | 237.60 | 309.60 | 437.80 | 327.20 | 334.70 | 434.40 | 370.70 | ||||||||||
| Net Income | 497.40 | 550.40 | 612.10 | 372.40 | 905.30 | 748.20 | 740.50 | 648.40 | 462.70 | 498.40 | ||||||||||
| EPS | 4.14 | 4.59 | 5.10 | 3.10 | 7.54 | 6.23 | 6.17 | 5.40 | 3.85 | 4.15 | ||||||||||
| DPS | 0.83 | 0.83 | 0.50 | 0.50 | 0.50 | 0.00 | 0.00 | 0.50 | 1.50 | 1.50 | ||||||||||
| Payout ratio | 0.20 | 0.18 | 0.10 | 0.16 | 0.07 | 0.00 | 0.00 | 0.09 | 0.39 | 0.36 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
Peers & Comparison
Health CareBiotechnology
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Biocon Ltd | 62.61 | 1.29 | 0.62% |
| Hester Biosciences Ltd | 47.63 | 4.39 | 0.54% |
| Panacea Biotec Ltd | -32.39 | 1.28 | — |
| Zenotech Laboratories Ltd | 33.78 | 4.76 | — |
Price Comparison
Compare BIOCON with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Decreased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has decreased by 1.56%
Shareholding Pattern
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Biocon Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
SBI FUNDS MANAGEMENT PVT LTD#SBI MF-SBI CONTRA FUND DIRECT PL GROWTH Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.0844% | Percentage of the fund’s portfolio invested in the stock 1.66% | Change in the portfolio weight of the stock over the last 3 months 0.31% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 8/103 (+8) |
Mirae Asset Large Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.9170% | Percentage of the fund’s portfolio invested in the stock 0.77% | Change in the portfolio weight of the stock over the last 3 months 0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 51/70 (0) |
SBI Balanced Advantage Fund - Direct Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.7912% | Percentage of the fund’s portfolio invested in the stock 0.90% | Change in the portfolio weight of the stock over the last 3 months 0.36% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 64/109 (+13) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 7, 2023
Dividend/Share
₹1.50
Ex DateEx Date
Jul 7, 2023
Cash Dividend
Ex DateEx DateJun 30, 2022
Dividend/Share
₹0.50
Ex DateEx Date
Jun 30, 2022
Cash Dividend
Ex DateEx DateJul 18, 2019
Dividend/Share
₹0.50
Ex DateEx Date
Jul 18, 2019
Cash Dividend
Ex DateEx DateJul 19, 2018
Dividend/Share
₹1.00
Ex DateEx Date
Jul 19, 2018
Cash Dividend
Ex DateEx DateJul 20, 2017
Dividend/Share
₹1.00
Ex DateEx Date
Jul 20, 2017
News & Opinions
News Video
Q2 Review: Biocon PAT Doubles, Revenue Surges | BQ Prime
3 weeks ago•BQ Prime
Biocon Q2 Results Review - Delay In New Approvals Drags Biosimilar Prospects: Motilal Oswal
3 weeks ago•Bloomberg Quint
Stocks To Watch: Coal India, ONGC, Glenmark Pharma, LIC, Grasim Industries, Eicher Motors, SAIL, Biocon
3 weeks ago•Bloomberg Quint
Biocon Q2 results: Net profit more than doubles to Rs 172.7 crore
4 weeks ago•Moneycontrol
Stocks To Watch: Pidilite Industries, Biocon, HDFC Life, Tata Power, BHEL, Power Finance, Titagarh Rail, Lupin
1 month ago•Bloomberg Quint
Kiran Mazumdar-Shaw Started With Rs 10,000 & Then Built Biocon Into A Rs 50,000 Cr Biz - News18
1 month ago•News18
Stocks to Watch: Wipro, Biocon, IndiGo, Bajaj Finance, Glenmark, HUDCO, and Others - News18
1 month ago•News18
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 21.56%, vs industry avg of 19.45%
Increasing Market Share
Over the last 5 years, market share increased from 84.32% to 92.03%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 4.44%, vs industry avg of 8.68%